2017 saw the publication of new classifications for epilepsy and seizure types, which emphasize the importance of understanding the underlying disease mechanisms. This aetiology-based approach is already beginning to inform developments in therapies and trial design in the epilepsies.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The dysregulation of miRNAs in epilepsy and their regulatory role in inflammation and apoptosis
Functional & Integrative Genomics Open Access 31 August 2023
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Scheffer, I. E. et al. ILAE classification of the epilepsies: position paper of the ILAE Commission for Classification and Terminology. Epilepsia 58, 512–521 (2017).
Fisher, R. S. et al. Operational classification of seizure types by the International League Against Epilepsy: position paper of the ILAE commission for classification and terminology. Epilepsia 58, 522–530 (2017).
Fisher, R. S. et al. Instruction manual for the ILAE 2017 operational classification of seizure types. Epilepsia 58, 531–542 (2017).
[No authors listed]. Proposal for revised classification for epilepsies and epileptic syndromes. Epilepsia 30, 389–399 (1989).
Devinsky, O. et al. Cannabidiol in patients with treatment-resistant epilepsy: an open-label intervention trial. Lancet Neurol. 15, 270–278 (2016).
Devinsky, O. et al. Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome. N. Engl. J. Med. 376, 2011–2020 (2017).
Wu, Y. W. et al. Incidence of Dravet syndrome in a US population. Pediatrics 136, e1310–e1315 (2015).
Dwivedi, R. et al. Surgery for drug-resistant epilepsy in children. N. Engl. J. Med. 377, 1639–1647 (2017).
Kim, D. W. et al. Surgical treatment of non-lesional neocortical epilepsy: long-term longitudinal study. JAMA Neurol, 74, 324–331 (2017).
O'Callaghan, F. J. et al. Safety and effectiveness of hormonal treatment versus hormonal treatment with vigabatrin for infantile spasms (ICISS): a randomised, multicentre, open-label trial. Lancet Neurol. 16, 33–42 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.M.Z. has received honoraria for educational activities and advisory boards from GW Pharma, paid to his institution's charitable account. He was Chair of the International League Against Epilepsy Commission for Classification and Terminology from 2013–2017. A.B. declares no competing interests.
Rights and permissions
About this article
Cite this article
Zuberi, S., Brunklaus, A. Precision medicine drives epilepsy classification and therapy. Nat Rev Neurol 14, 67–68 (2018). https://doi.org/10.1038/nrneurol.2017.190
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2017.190
This article is cited by
-
The dysregulation of miRNAs in epilepsy and their regulatory role in inflammation and apoptosis
Functional & Integrative Genomics (2023)
-
Impact of predictive, preventive and precision medicine strategies in epilepsy
Nature Reviews Neurology (2020)